NEW STUDY. Digital memory test and a blood sample – this combination will be tested for its potential to identify early Alzheimer’s disease in a new research study. Over a hundred healthcare centers are part of the study that is now inviting participants to sign up. At least 3,000, preferably many more participants are needed for the study to be successful. The REAL AD study is the first of its…
Henrik Zetterberg honored by the Alzheimer’s Drug Discovery Foundation
DISTINCTION. Hello there, Henrik Zetterberg! And congratulations on receiving this year’s Melvin R. Goodes Prize, an international award presented by the Alzheimer’s Drug Discovery Foundation. How does it feel to receive this award? – It’s absolutely thrilling! Our work revolves around developing objective and quantitative tests to measure the extent of brain changes in Alzheimer’s disease and other dementia-causing conditions. The fantastic thing is that these markers really work, as…
Nicholas Ashton joins the list of the world’s most cited scientists
DISTINCTIONS. This year sees two newcomers from the University of Gothenburg on the Clarivate Analytics list of the world’s most cited researchers: Nicholas Ashton and Deliang Chen. In total, 14 of our researchers now belong to the top percentage of those most frequently cited by other researchers. Nicholas Ashton is a researcher at the Institute of Neuroscience and Physiology, working within clinical neurochemistry. As a relatively young researcher, it feels…
Kaj Blennow receives international research award
AWARD. This year, Copenhagen University Hospital – Rigshospitalet’s International KFJ Award goes to Swedish Professor Kaj Blennow, who is recognized as a global leader in the development of biomarkers for the diagnosis of Alzheimer’s disease. The use of biomarkers in clinical practice and research is rapidly advancing in healthcare. In the field of neurodegenerative diseases, such as Alzheimer’s disease, Swedish Professor Kaj Blennow is one of the forefront figures in…
New blood test gives very high accuracy to screen for Alzheimer’s disease
NEW STUDY. A new blood test called p-tau217 shows promise as an Alzheimer’s disease biomarker, and when used in a two-step workflow very high accuracy to either identify or exclude brain amyloidosis, the most important and earliest pathology. That is an innovation now presented by researchers at the University of Gothenburg, together with colleagues at University of Lund and in Montreal, Canada. In recent years, a lot of effort has…